vidarabine has been researched along with Cardiovascular Stroke in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albrecht-Küpper, B; Bräunig, JH; Seifert, R | 1 |
| Bravo, CA; Pachon, R; Vatner, DE; Vatner, SF; Zhang, J | 1 |
| Abidi, MH; Braun, TM; Ibrahim, RB; Khaled, YA; Krijanovski, OI; Levine, JE; Mineishi, S; Peres, E | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
4 other study(ies) available for vidarabine and Cardiovascular Stroke
| Article | Year |
|---|---|
Adenylyl cyclase regulation in heart failure due to myocardial infarction in rats.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Blood Pressure; Heart Failure; Heart Rate; Heart Ventricles; Isoenzymes; Male; Myocardial Infarction; Nucleotides; Rats; Rats, Wistar; Ventricular Function; Vidarabine | 2014 |
A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.
Topics: Adenosine; Adenylyl Cyclases; Animals; Antiviral Agents; Arterial Pressure; Cardiotonic Agents; Coronary Vessels; Drug Approval; Enzyme Inhibitors; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Sus scrofa; United States; United States Food and Drug Administration; Vidarabine | 2016 |
Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.
Topics: Adult; Aged; Anthracyclines; Arrhythmias, Cardiac; Busulfan; Female; Heart Diseases; Heart Failure; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2010 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |